Canopy GrowthHAM:11L +2.71%59 Current Ratio is 3.34 as of Mar. 2026, which is 41% below its 10-year median of 5.67. GuruFocus rates HAM:11L with a GF Score™ of 59/100 and a GF Value™ of €0.65 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 996 Drug Manufacturers companies, Canopy Growth ranks better than 71.18% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Canopy Growth's current ratio for the quarter that ended in Mar. 2026 was 3.34.
Canopy Growth has a current ratio of 3.34. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Canopy Growth's Current Ratio or its related term are showing as below:
HAM:11L'
s Current Ratio Range Over the Past 10 Years
Min: 1.11 Med: 5.67 Max: 11.95
Current: 3.34
During the past 13 years, Canopy Growth's highest Current Ratio was 11.95. The lowest was 1.11. And the median was 5.67.
HAM:11L's Current Ratio is ranked better than 71.18% of 996
companies
in the Drug Manufacturers industry
Industry Median: 2
vs HAM:11L: 3.34
Canopy Growth (HAM:11L) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Canopy Growth Current Ratio Related Terms
Canopy Growth Current Ratio Historical Data
* Premium members only.
The historical data trend for Canopy Growth's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Canopy Growth's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Canopy Growth Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Canopy Growth's Current Ratio distribution charts can be found below:
* The bar in red indicates where Canopy Growth's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Canopy Growth (HAM:11L) has a Current Ratio of 3.34 as of Mar. 2026. This is 41% below median its historical median of 5.67. Over the past decade, Canopy Growth's Current Ratio has ranged from 1.11 to 11.95. According to the industry distribution chart, Canopy Growth ranks #287 out of 996 companies in the Drug Manufacturers industry, placing it in the top 28.8%.
Is Canopy Growth's Current Ratio too high?
Canopy Growth's current Current Ratio of 3.34 is 41% below median its 10-year median of 5.67. Over the past 10 years, this metric has ranged from a low of 1.11 to a high of 11.95. The Drug Manufacturers industry median Current Ratio is 2.00. Canopy Growth's value of 3.34 is 67% above this industry median. Based on the distribution chart, Canopy Growth ranks #287 out of 996 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Canopy Growth has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Canopy Growth's Current Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Canopy Growth ranks #287 out of 996 companies for Current Ratio. This puts Canopy Growth in the upper half of its industry. The industry median Current Ratio is 2.00. Canopy Growth's value of 3.34 is 67% above this benchmark. Historically, Canopy Growth's own Current Ratio has ranged from 1.11 to 11.95 over the past decade. While the company's 10-year median is 5.67 vs. the industry median of 2.00, Canopy Growth has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 996 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Canopy Growth's current Current Ratio of 3.34 is 67% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Canopy Growth's current Current Ratio is 3.34, which is 41% below median its own 10-year median of 5.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Canopy Growth stock overvalued right now?
Based on GuruFocus' analysis, Canopy Growth (HAM:11L) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.65, compared to a current price of €0.85 — trading 30.8% above its estimated fair value. The current Current Ratio is 3.34, which is 41% below median its 10-year median of 5.67 and 67% above the Drug Manufacturers industry median of 2.00. Canopy Growth's overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Canopy Growth (HAM:11L), the current Current Ratio is 3.34 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Canopy Growth (HAM:11L) Overvalued in 2026?
Based on GuruFocus' analysis, Canopy Growth stock appears to be overvalued.
The current stock price of €0.85 is trading 30.8% above its estimated GF Value™ of €0.65.
GuruFocus considers Canopy Growth to be Significantly Overvalued.
Key valuation signals for HAM:11L:
Current Ratio: 3.34 (41% below median its 10-year median of 5.67)
GF Value™: €0.65 vs. price of €0.85 (30.8% above fair value)
Industry Position: 67% above the Drug Manufacturers median (#287 of 996)
No single metric tells the full story. See the HAM:11L stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Canopy Growth Corp is a cannabis company that produces, distributes, and sells a diverse range of cannabis and cannabis-related products for adult-use and medical purposes under a portfolio of distinct brands in Canada. The Company supplies cannabis products in Canada, Europe, and Australia. It is focused on the medical and adult-use cannabis markets in Canada, offering a broad portfolio of brands and formats for medical cannabis patients and adult-use consumers. The Company operates through two reportable segments: Cannabis, which generates maximum revenue and includes the production, distribution, and sale of cannabis and cannabis-related products, and Storz & Bickel, which includes the production, distribution, and sale of vaporizers and accessories.
59GF Score
Get the complete analysis for HAM:11L
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:11L has been successfully added to your 
